Skip to main content
OpenTrials
Completed

NCT Number: NCT04995614

Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223

The aim of the current prospective multicenter study is to evaluate cancer-specific and bone metastases related HR-QoL, psychological distress and fatigue in mCRPC patients before, during and after treatment with radium-223 in daily practice. Furthermore, the investigators aim to determine patient groups with identical health-related quality of life patterns over time, in order to identify variables related to health-related quality of life deterioration during the course of treatment, as patients with health-related quality of life deterioration may need specific attention to preserve health-related quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands

Loading trial locations.

About this study

Radium-223 is a registered treatment option for patients with symptomatic bone metastatic castration-resistant prostate cancer. Previously, the phase 3 ALSYMPCA trial demonstrated that radium-223 improved overall survival and prolonged the time to the first symptomatic skeletal event and the time to first opioid use, irrespective of prior docetaxel chemotherapy. Subsequent analysis of the ALSYMPCA study showed that a significantly higher percentage of patients receiving radium-223 experienced meaningful HR-QoL improvement, as measured by the EQ-5D questionnaire and the FACT-P questionnaire, when compared to patients treated with placebo. However, studies evaluating health-related quality of life, psychological distress and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 in daily practice are lacking.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Metastatic castration-resistant prostate cancer;
  • Undergoing treatment with radium-223 according to standard of care;
  • Ability to comply with the study protocol, including completion of questionnaires on health-related quality of life;
  • Written informed consent to the treating physician at the hospital site.

Exclusion criteria

  • Prior radium-223 therapy;
  • Impaired cognitive functioning and/or illiteracy.

Treatment and study plan

Radium-223

Drug

Prospective observational cohort study investigating patient-reported outcomes

Other names: Xofigo

Primary outcomes

  1. Cancer-specific health-related quality of life

    Time frame: 6 months

    Measured with the European Organization for Research and Treatment of Cancer (EORTC) core QoL questionnaire (QLQ-C30). All items are rated on a 4-point Likert-type response scale of 1 ("not at all") to 4 ("very much"), with the exception of the global health status scale items, which are rated from 1-7. Each subscale will be linearly transformed to a 0-100 scale, according to the EORTC scoring manuals. For the functional and global scales, high scores indicate high level of functioning. For the symptom scales, high scores indicate high symptom burden. Clinically relevant changes (CRCs) in EORTC scores are defined as small (5-10 points), moderate (10-20 points), or large (>20 points).

  2. Bone metastases related health-related quality of life

    Time frame: 6 months

    Measured with the European Organization for Research and Treatment of Cancer (EORTC) bone metastases module (BM-22). All items are rated on a 4-point Likert-type response scale of 1 ("not at all") to 4 ("very much"). Each subscale will be linearly transformed to a 0-100 scale, according to the EORTC scoring manuals. For the functional and global scales, high scores indicate high level of functioning. For the symptom scales, high scores indicate high symptom burden. Clinically relevant changes (CRCs) in EORTC scores are defined as small (5-10 points), moderate (10-20 points), or large (>20 points).

Secondary outcomes

  1. Intensity and location of bone pain

    Time frame: at baseline

    Measured with the Brief Pain Inventory Short Form (BPI-SF). The pain severity items are rated on 0-10 scales, with 0 indicating "no pain" and 10 indicating "worst possible pain". Clinically relevant pain is defined as a score of ≥4 on the average pain severity scale.

  2. Psychological distress

    Time frame: 6 months

    Measured with the Hospital Anxiety and Depression Scale (HADS). The HADS contains a 7-item anxiety and a 7-item depression subscale. All items are scored on a 4-point Likert-scale ranging from scores 0 ('never') to 3 ('almost always'). A total score of 11 or higher indicates psychological distress. The clinically relevant chage in HADS subscale scores is defined as 1.5 points change, and 3 points change for the total HADS score.

  3. Fatigue

    Time frame: 6 months

    Measured with the Checklist Individual Strength - Fatigue subscale (CIS-Fatigue). The CIS-Fatigue contains 8 items, and each item is scored on a 7-point Likert scale ranging from "Yes, that is true" to "No, that is not true". A score of 35 or higher on the subscale fatigue severity indicates severe feelings of fatigue.

Other outcomes

  1. Overall survival

    Time frame: 24 months

    Defined as the time between the first radium-223 injection and either death from any cause or the last follow-up

  2. Number of radium-223 injections

    Time frame: 6 months

    Number of radium-223 injections

  3. Trajectory analysis of health-related quality of life patterns over time

    Time frame: 6 months

    Individual responses are classified based upon similar patterns in health-related quality of life, according to the EORTC QLQ-C30 summary score. Summary scores will be classified as <60 (low), 60-80 (intermediate) and >80 (high). Changes in summary scores over time will be classified as deteriorated, stable low (low at all time points), stable intermediate, stable high, improved and fluctuating.

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Collaborators

  • Bayer

Registry information

Official study title

The Evaluation of the Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic Castration-resistant Prostate Cancer Patients Treated With Radium-223 Therapy, a Multicenter, Prospective Observational Cohort Study

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Aug 9, 2021
Registry last updated
Aug 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.